JERSEY
CITY, N.J., July 22,
2024 /PRNewswire/ -- The high cost of cancer care is
limiting affordability and availability of care for patients
throughout the United States. RCCA, the largest by volume
provider of cancer services in New
Jersey and a leader in providing all forms of innovative
cancer care in an NCI designated university academic setting and in
the community throughout New
Jersey, Connecticut,
Maryland and D.C. is partnering
with OMI to offer VBC solutions for common cancers so to reduce
total cost of care while maintaining the highest quality clinical
outcomes. OMI is a New Jersey
based VBC accelerator company that partners with providers of all
specialties across the United
States to enable specialty participation and success in VBC
programs.
RCCA and OMI, starting with breast cancer, will be engaging all
commercial payers to initiate VBC programs throughout RCCA's
network to augment its existing VBC participation with CMS.
About Outcomes Matter Innovations:
Outcomes Matter Innovations, LLC (OMI) is Jersey City based company focused on
technology enablement that facilitates a new business model in
Value-Based Care Reimbursement for Specialty physicians, as well as
management services for established healthcare providers throughout
the Northeast. Founded in 2018, they work with specialty
physicians to develop clinical treatment pathways in their
respective specialties for conditions which have a high total cost
of care and high-variability in treatment. Using the expertise and
data provided by specialty physician partners, OMI develops
customized technology for the physician to make decisions and track
outcomes at the point of care with the goal of improving outcomes
and decreasing the total cost of care.
About RCCA
Established in 2012, Regional Cancer Care Associates (RCCA) has
100+ cancer specialists providing community-based care in 26
offices in New Jersey,
Connecticut, Maryland, and the Washington, DC area. RCCA oncologists and
hematologists see more than 27,000 new patients each year and
provide care to more than 260,000 established patients,
collaborating closely with those patients' other physicians. RCCA
specialists offer patients innovative therapies, including
immunotherapies and targeted therapy, as well as access to
approximately 300 clinical trials. In addition to serving patients
who have solid tumors, blood-based cancers, and benign blood
disorders, RCCA care centers also provide infusion services to
people with a number of non-oncologic conditions—including multiple
sclerosis, Crohn's disease, asthma, iron-deficiency anemia,
and rheumatoid arthritis—who take intravenously-administered
medications.
Contact:
Alison Brown
info@omimanagement.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/regional-cancer-care-associates-rcca-and-outcomes-matter-innovations-omi-announce-agreement-to-offer-value-based-care-vbc-solutions-in-oncology-302201949.html
SOURCE Outcomes Matter Innovations, LLC